Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Blood AdvancesOpen Access

Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study

View Full Paper
Ask AI
Bookmark
Share

Authors

OTOlivier TournilhacKBKrimo BouabdallahSLSolene Lecolant

Discussion

Loading...

Member takes

Overview

Phase II trial reports 46.5% overall response rate in relapsed/refractory peripheral T-cell lymphoma patients, indicating promise for targeted therapy.

Key Points

  • The overall response rate achieved was 46.5%, indicating a significant response in treatment.
  • Adverse events were common; 55% experienced grade 3-4 neutropenia during induction treatment.
  • Patients with anaplastic large cell lymphoma expressed higher efficacy, presenting notable response and survival rates.
  • High baseline soluble CD30 levels negatively impacted response and survival metrics in treated patients.

Cite This Study

Tournilhac et al. (2025) studied this question.

synapsesocial.com/papers/68c1b18554b1d3bfb60e8627https://doi.org/10.1182/bloodadvances.2024015787
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data2024
  2. 2Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma2025 · 1 citations
  3. 3Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study2025
  4. 4Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis2025
  5. 5Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.2024 · 5 citations